Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kesimpta by Quarter
Kesimpta — US B-Cell TRx Share Gain (percentage points) (%)
Novartis Kesimpta: 4.5% in Q3 2026.
Latest, Q3 2026
4.5%
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
“Appendix | USD m, % cc | • TRx growth1 outpacing the market, +3%pts in MS (~16% share) and +4.5%pts in B-cell class”
Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Reported in Quarterly Investor Presentations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kesimpta — US B-Cell TRx Share Gain (percentage points) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 4.5% | – | Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗ |
| Q2 2026 | Jun 30, 2026 | 2.5% | – | Novartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗ |
| Q1 2026 | Mar 31, 2026 | 1.5% | – | Novartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗ |
| Q4 2025 | Dec 31, 2025 | 2.4% | – | Novartis Official IR / Sustainability Report — q4-2025-investor-presentation.pdf ↗ |
Cite this data
StockData. (2026). Novartis Kesimpta (%), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kesimpta-us-bcell-trx-gain-pts
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.